Sterol 14 Alpha-Demethylase Inhibitor Drug Pipeline Research 2024
April 11, 2024 09:23 ET
|
Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Sterol 14 Alpha-Demethylase Inhibitor - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering."Sterol 14...
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
February 04, 2024 15:29 ET
|
Pliant Therapeutics, Inc.
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts ...
Sunrun Multifamily Rooftop Solar Installation Cuts Energy Bills for 100 Low-Income Homes
January 24, 2024 08:00 ET
|
Sunrun Inc.
SAN FRANCISCO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Solar on Multifamily Affordable Housing (SOMAH) Program, St. Mary’s Elderly Housing Corporation, and Asian Pacific Environmental Network have...
Next.e.GO Mobile and cylib announcing cooperation to develop sustainable recycling processes for lithium-ion batteries
December 14, 2023 07:30 ET
|
Next.e.GO N.V.
e.GO innovative producer of urban battery electric vehicles and cylib announcing cooperation to develop sustainable lithium-ion battery recycling processes
Wedding Photography Market Size to Hit USD 36.80 Billion by 2030 | Exclusive Report by Fortune Business Insights™
November 22, 2023 01:56 ET
|
Fortune Business Insights
Pune, India, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The global wedding photography market size was USD 20.44 billion in 2022 and is set to expand from USD 21.83 billion in 2023 to USD 36.80 billion by...
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
November 13, 2023 16:30 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...
CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023
October 23, 2023 16:05 ET
|
CymaBay Therapeutics, Inc.
Cholestatic pruritus expert leads plenary discussion of correlated decreases in serum IL-31 levels and pruritus among patients with PBC treated with seladelpar A second presentation of baseline trial...
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
October 19, 2023 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...
CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
October 18, 2023 08:00 ET
|
CymaBay Therapeutics, Inc.
Results from the RESPONSE registrational study to be highlighted in oral presentation on Monday, November 13thFifth oral late-breaking presentation of seladelpar results at The Liver Meeting® NEWARK,...
New AI Survey from Notified and PRWeek Finds PR Pros Believe in the Power of the Technology, Want Education and Resources to Drive Meaningful Usage
October 10, 2023 10:00 ET
|
Notified
Data Reveals That a Majority of PR Pros Are Very Optimistic About AI, Believe It Can ‘Notably’ Impact Strategy Development